 |
Op Eds / Perspectives
Date
|
Title
|
Author
|
| July 8, 2008 |
Opinion:
Is there an important pattern in the seemingly
uninterrupted failure of drugs and biologics?
|
Greg Wasson, Advocate |
| February i,
2008 |
Gains Come with Risks, Sometimes Personal Costs? |
Peggy Willocks, Advocate |
| December 10,
2007 |
Profit Over Common Sense |
Paula Wittekind, Advocate |
| August 10,
2006 |
New data has patient advocates still asking: Why did Amgen halt
its GDNF trials? |
Linda
Herman, Advocate |
| June 5,
2006 |
Putting a Name To It |
Paula Wittekind, Editor, Grassroots Connection |
| May 24,
2006 |
GDNF poses troubling questions for doctors and drug maker |
|
| May 17,2006 |
What will FDA approval of Exelon mean for the PD community? |
Perry Cohen,
Director, Parkinson Pipeline Project |
| March 20, 2006 |
PRECEPT Trial Participant and PD
Advocate
CEP-1347 results disappointing, but clinical trials still best hope
for a cure |
Jean Burns, Advocate |
| February 17, 2006 |
Grassroots
responses: The Lancet Neurology:
GDNF in treatment of Parkinson's disease
|
Jean Burns, Advocate |
| July 12, 2005
|
Open letter to
the trial participants using GDNF |
Peg Willocks, Advocate |
| July 11, 2005 |
Patients in UK Parkinson's disease study treated
unfairly
Amnews.com - The Advocate Messenger,
Letter to the Editor |
Lonnie Napier, State Representative,
Kentucky |
|
July 10, 2005 |
Amgen's GDNF
shows signs of effectiveness
LA Times, Business Section, letter to the editor,
Regarding "Study adds to dispute over drug by Amgen," July 2, 2005 |
Kristin Suthers |
| June 8, 2005 |
Court ruling denies patients
compassionate use of GDNF
|
Linda Herman,
Advocate |
| May 25, 2005 |
Cephalon, Inc. Halts Clinical Trial of CEP-1347 for Neuroprotection |
Linda Herman,
Advocate |
| May, 2005 |
GDNF and the Patient Perspective on New Therapy Development |
Perry Cohen,
Director, Parkinson Pipeline Project |
|
|
